Abstract Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control
through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of …

Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent
insulinotropic and glucagonostatic actions, trophic effects on the pancreatic β-cells, and …

The incretin hormone, glucagon-like peptide-1 (GLP-1), is now being used in the clinic to
enhance insulin secretion and reduce body weight in patients with type 2 diabetes. Although …

Abstract Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food
intake, and plays an important role in glucose homeostasis due to its stimulation of glucose …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

Glucagon‐like peptide 1 (GLP‐1) is a gut‐derived incretin hormone with the potential to
change diabetes. The physiological effects of GLP‐1 are multiple, and many seem to …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

Metabolic consequences of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the
result of enhanced glucose-stimulated insulin secretion, inhibition of glucagon release …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …